

09/757,011

=> d his

(FILE 'HOME' ENTERED AT 11:48:06 ON 05 SEP 2002)

FILE 'REGISTRY' ENTERED AT 11:48:12 ON 05 SEP 2002

L1 651982 S C4O/RF
L2 301176 S C4S/RF
L3 382103 S C3NS/RF
L4 235210 S C3NO/RF
L5 90000 S C7NO/RF
L6 165836 S C7NS/RF
L7 69355 S C8S/RF
L8 177510 S C8O/RF
L9 107795 S C7O2/RF
L10 2084270 S L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9
L11 STRUCTURE UPLOADED
L12 QUE L11
L13 2801 S L12 SUB=L10 FUL
L14 STRUCTURE UPLOADED
L15 QUE L14
L16 50 S L15 SUB=L13 SAM
L17 STRUCTURE UPLOADED
L18 QUE L17
L19 50 S L18 SUB=L13 SAM
L20 1817 S L18 SUB=L13 FUL

FILE 'STNGUIDE' ENTERED AT 12:12:41 ON 05 SEP 2002

FILE 'REGISTRY' ENTERED AT 12:21:27 ON 05 SEP 2002

FILE 'CAPLUS' ENTERED AT 12:21:36 ON 05 SEP 2002

L21 291 S L20
L22 154 S L21 AND PATENT/DT
L23 137 S L21 NOT L22
L24 1 S L23 AND 2002/SO
L25 14 S L23 AND 2001/SO
L26 7 S L23 AND 2000/SO
L27 14 S L23 AND 1999/SO
L28 15 S L23 AND 1998/SO
L29 88 S L23 NOT (L24 OR L25 OR L26 OR L27 OR L28)
L30 ANALYZE L29 1- RN : 2001 TERMS

FILE 'REGISTRY' ENTERED AT 12:25:22 ON 05 SEP 2002

L31 1 S 159768-75-9/RN

FILE 'CAPLUS' ENTERED AT 12:26:01 ON 05 SEP 2002

L32 12 S L29 AND PEPTIDE
L33 94 S L21 AND PEPTIDE

FILE 'REGISTRY' ENTERED AT 12:27:02 ON 05 SEP 2002

FILE 'REGISTRY' ENTERED AT 12:29:27 ON 05 SEP 2002

FILE 'STNGUIDE' ENTERED AT 12:31:45 ON 05 SEP 2002

FILE 'REGISTRY' ENTERED AT 12:36:49 ON 05 SEP 2002

FILE 'CAPLUS' ENTERED AT 12:41:42 ON 05 SEP 2002

09/757,011

L34 197 S L21 NOT L33
L35 159 S L34 NOT (L24 OR L25 OR L26 OR L27 OR L28)
L36 6 S L35 AND (SCHIZOPHRENIA OR EPILEPSY OR SPASTICITY OR (MUSCLE S

=> d bib abs hitstr 1-6

~~136~~ ANSWER 1 OF 6 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 2002:90035 CAPLUS

DN 136:135020

TI Synthesis of amino acid derivatives for pharmaceutical use as glycine transport protein antagonists

IN Moltzen, Ejner Knud; Smith, Garrick Paul; Krog-Jensen, Christian; Bogeso, Klaus Peter

PA H. Lundbeck A/S, Den.

SO PCT Int. Appl., 35 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002008216	A1	20020131	WO 2001-DK510	20010719
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	DK 2000-1124	A	20000721		
OS	MARPAT 136:135020				
GI					



AB Title compds. (e.g., (I)), were prep'd. and tested as inhibitors of the glycine transport protein, for use in treatment of diseases responsive to ligands of the glycine transporter. Condensation of a 3-activated-prop-1-yl comp'd. with an N-methylated amino acid ester, followed by ester hydrolysis, gave I-type compds. or their salts. Alternately, a suitable 3-aminoprop-1-yl comp'd. was reacted with Et bromoacetate. In vivo inhibition tests using human GlyT-1b, I had IC50 of 470 (sic).


IT 392286-80-5

RL: PAC (Pharmacological activity); BIOL (Biological study)
(prepn. of amino acid derivs. for pharmaceutical use as glycine transport protein antagonists)

09/757,011

RN 392286-80-5 CAPLUS

CN Glycine, N-[2-[1-(4-chlorophenyl)-1,3-dihydro-5-(4-methylphenyl)-1-isobenzofuranyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



IT 392286-35-0P 392286-40-7P 392286-41-8P

392286-42-9P 392286-43-0P 392286-49-6P

392286-51-0P 392286-56-5P 392286-57-6P


392286-63-4P 392286-69-0P 392286-70-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of amino acid derivs. for pharmaceutical use as glycine transport protein antagonists)

RN 392286-35-0 CAPLUS

CN Glycine, N-[3-[1,3-dihydro-1-(4-methylphenyl)-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 392286-40-7 CAPLUS

CN Glycine, N-[3-[4-chloro-1-(4-chlorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)


09/757,011



● HCl

RN 392286-41-8 CAPLUS


CN Alanine, N-[3-[5-chloro-1-(4-chlorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 392286-42-9 CAPLUS

CN Glycine, N-[3-[6-chloro-1-(4-chlorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 392286-43-0 CAPLUS


CN Glycine, N-[3-[6-chloro-1,3-dihydro-1-(4-methylphenyl)-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

09/757,011




● HCl

RN 392286-49-6 CAPLUS
CN Glycine, N-[3-[5-cyano-1-(4-fluoro-3-methylphenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 392286-51-0 CAPLUS
CN Glycine, N-[3-[5-cyano-1,3-dihydro-1-(4-methoxyphenyl)-1-isobenzofuranyl]propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 392286-56-5 CAPLUS
CN Glycine, N-[3-[5-bromo-1-(4-chlorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)

09/757,011




RN 392286-57-6 CAPLUS

CN Glycine, N-[2-[1-(4-chlorophenyl)-1,3-dihydro-3,3-dimethyl-1-isobenzofuranyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 392286-63-4 CAPLUS

CN Glycine, N-[3-[1-(4-chlorophenyl)-1,3-dihydro-5-(4-methylphenyl)-1-isobenzofuranyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 392286-69-0 CAPLUS


CN Glycine, N-[2-[1-(4-chlorophenyl)-1,3-dihydro-5-(2-methylphenyl)-1-isobenzofuranyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 392286-70-3 CAPLUS

09/757,011

CN Glycine, N-[2-[1-(4-chlorophenyl)-5-(2,5-dichlorophenyl)-1,3-dihydro-1-isobenzofuranyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




IT 392286-28-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of amino acid derivs. for pharmaceutical use as glycine transport protein antagonists)

RN 392286-28-1 CAPLUS

CN Glycine, N-[3-[5-cyano-1-(4-fluorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 392286-29-2P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of amino acid derivs. for pharmaceutical use as glycine transport protein antagonists)

RN 392286-29-2 CAPLUS

CN Glycine, N-[3-[5-cyano-1-(4-fluorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




IT 392286-30-5P 392286-31-6P 392286-32-7P
392286-33-8P 392286-34-9P 392286-36-1P
392286-37-2P 392286-38-3P 392286-39-4P
392286-44-1P 392286-45-2P 392286-46-3P
392286-47-4P 392286-48-5P 392286-52-1P
392286-55-4P 392286-59-8P 392286-60-1P
392286-61-2P 392286-62-3P 392286-64-5P
392286-65-6P 392286-66-7P 392286-67-8P
392286-68-9P 392286-71-4P 392286-72-5P

392286-73-6P 392286-74-7P 392286-75-8P
 392286-76-9P 392286-77-0P 392286-78-1P
 392286-79-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of amino acid derivs. for pharmaceutical use as glycine transport protein antagonists)

RN 392286-30-5 CAPLUS


CN Glycine, N-[3-[5-cyano-1-(4-fluorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 392286-31-6 CAPLUS

CN Glycine, N-[3-[5-cyano-1-(4-fluorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 392286-32-7 CAPLUS


CN Glycine, N-[3-[1-(3-chlorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

09/757,011




● HCl

RN 392286-33-8 CAPLUS
CN Glycine, N-[3-[1,3-dihydro-1-[3-(trifluoromethyl)phenyl]-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 392286-34-9 CAPLUS
CN Butanoic acid, 2-[[3-[1,3-dihydro-1-[3-(trifluoromethyl)phenyl]-1-isobenzofuranyl]propyl]methylamino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 392286-36-1 CAPLUS
CN Glycine, N-[3-[1-(4-fluorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

09/757,011




● HCl

RN 392286-37-2 CAPLUS
CN Alanine, N-[3-[1-(4-fluorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 392286-38-3 CAPLUS
CN Butanoic acid, 2-[3-[1-(4-fluorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]methyamino]-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 392286-39-4 CAPLUS
CN Glycine, N-[3-[4-chloro-1-(4-fluoro-3-methylphenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

09/757,011




● HCl

RN 392286-44-1 CAPLUS
CN Glycine, N-[3-[6-chloro-1,3-dihydro-1-(4-methoxyphenyl)-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 392286-45-2 CAPLUS
CN Glycine, N-[3-[1-(4-chlorophenyl)-5-fluoro-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 392286-46-3 CAPLUS
CN Glycine, N-[3-[5-fluoro-1,3-dihydro-1-(4-methoxyphenyl)-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)

09/757,011




● HCl

RN 392286-47-4 CAPLUS
CN Glycine, N-[3-[1-(4-fluorophenyl)-1,3-dihydro-5-(trifluoromethyl)-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 392286-48-5 CAPLUS
CN Alanine, N-[3-[1-(4-fluorophenyl)-1,3-dihydro-5-(trifluoromethyl)-1-isobenzofuranyl]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 392286-52-1 CAPLUS
CN Glycine, N-[2-[5-cyano-1-(4-fluorophenyl)-1,3-dihydro-1-isobenzofuranyl]ethyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


09/757,011



● HCl


RN 392286-55-4 CAPLUS

CN Alanine, N-[3-(1,3-dihydro-3,3-dimethyl-1-phenylbenzo[c]thien-1-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 392286-59-8 CAPLUS

CN Alanine, N-[3-[5-chloro-1,3-dihydro-1-(2-thienyl)-1-isobenzofuranyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 392286-60-1 CAPLUS

CN Butanoic acid, 2-[[3-[5-chloro-1,3-dihydro-1-(2-thienyl)-1-isobenzofuranyl]propyl]methylamino]- (9CI) (CA INDEX NAME)




RN 392286-61-2 CAPLUS

CN Alanine, N-[3-(1,3-dihydro-3-methyl-1-phenyl-1-isobenzofuranyl)propyl]-N-


09/757,011

methyl- (9CI) (CA INDEX NAME)




RN 392286-62-3 CAPLUS

CN Glycine, N-[2-[1-(4-chlorophenyl)-1,3-dihydro-5-(4-methoxyphenyl)-1-isobenzofuranyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 392286-64-5 CAPLUS

CN Glycine, N-[3-[1-(4-chlorophenyl)-1,3-dihydro-5-(4-methoxyphenyl)-1-isobenzofuranyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 392286-65-6 CAPLUS


CN Glycine, N-[3-[1-(4-chlorophenyl)-1,3-dihydro-5-[4-(trifluoromethyl)phenyl]-1-isobenzofuranyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 392286-66-7 CAPLUS
 CN Glycine, N-[2-[1,5-bis(4-chlorophenyl)-1,3-dihydro-1-isobenzofuranyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 392286-67-8 CAPLUS
 CN Glycine, N-[2-[1-(4-chlorophenyl)-5-(5-chloro-2-thienyl)-1,3-dihydro-1-isobenzofuranyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 392286-68-9 CAPLUS
 CN Glycine, N-[2-[1-(4-chlorophenyl)-1,3-dihydro-5-(3-methylphenyl)-1-isobenzofuranyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 392286-71-4 CAPLUS
 CN Glycine, N-[2-[1-(4-chlorophenyl)-1,3-dihydro-5-[3-(4-chlorophenyl)phenyl]-1-isobenzofuranyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)

(trifluoromethyl)phenyl]-1-isobenzofuranyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 392286-72-5 CAPLUS

CN Glycine, N-[3-[1-(4-chlorophenyl)-1,3-dihydro-5-[3-(trifluoromethyl)phenyl]-1-isobenzofuranyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 392286-73-6 CAPLUS


CN Glycine, N-[2-[1-(4-chlorophenyl)-5-(3,4-dichlorophenyl)-1,3-dihydro-1-isobenzofuranyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 392286-74-7 CAPLUS


CN Glycine, N-[3-[1,5-bis(4-chlorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)

09/757,011




RN 392286-75-8 CAPLUS

CN Glycine, N-[3-[1-(4-chlorophenyl)-1,3-dihydro-5-(3-methylphenyl)-1-isobenzofuranyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 392286-76-9 CAPLUS

CN Glycine, N-[3-[1-(4-chlorophenyl)-1,3-dihydro-5-(2-methylphenyl)-1-isobenzofuranyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 392286-77-0 CAPLUS


CN Glycine, N-[3-[1-(4-chlorophenyl)-5-(2,5-dichlorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)



09/757,011


RN 392286-78-1 CAPLUS

CN Glycine, N-[3-[1-(4-chlorophenyl)-5-(3,4-dichlorophenyl)-1,3-dihydro-1-isobenzofuranyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 392286-79-2 CAPLUS

CN Glycine, N-[3-[1-(4-chlorophenyl)-1,3-dihydro-5-[2-(trifluoromethyl)phenyl]-1-isobenzofuranyl]propyl]-N-methyl- (9CI) (CA INDEX NAME)



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT.

09/757,011

~~136~~ ANSWER 2 OF 6 CAPLUS COPYRIGHT 2002 ACS

~~AN~~ 2002:10422 CAPLUS

DN 136:70085

TI Preparation of amino acid benzophenone and sulfone derivatives as inhibitors of glycine uptake

IN Lowe, John Adams, III

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 48 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002000602	A1	20020103	WO 2001-IB1139	20010622
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 2001074407	A5	20020108	AU 2001-74407	20010622
	US 2002052401	A1	20020502	US 2001-897261	20010702
PRAI	US 2000-215692P	P	20000630		
	WO 2001-IB1139	W	20010622		
OS	MARPAT 136:70085				
GI					




AB Compds. I [A is Ph, naphthyl, benzothienyl, benzofuranyl, thienyl; a monocyclic aryl or heteroaryl ring contg. 0-4 heteroatoms or a bicyclic aryl or heteroaryl ring contg. 0-5 heteroatoms not contg. any adjacent ring oxygen atoms; Y is CO or SO₂ and is attached to the phenoxy group at the meta or para position; X and Z are H, (C₁-C₆) alkyl or alkoxy optionally substituted with 1-7 fluorine atoms, carboxy, carbalkoxy, carboxamido, alkylthio, sulfoxyl, sulfonyl, halo, nitro, cyano, amino, alkylamino or dialkylamino; R is H, alkyl, preferably Me] or their pharmaceutically acceptable salts were prepd. The title compds. exhibit activity as glycine transport inhibitors and thus can be used for the enhancement of cognition and the treatment of the pos. and neg. symptoms of **schizophrenia** and other psychoses in mammals, including humans. Thus, [[3-(4-benzoylphenoxy)-3-phenylpropyl]methylamino]acetic acid was prepd. by reaction of 3-chloro-1-bromo-1-phenylpropane with

4-benzoylphenol and sarcosine Et ester hydrochloride, followed by sapon.

IT 385436-18-0P 385436-35-1P 385436-37-3P
 385436-59-9P 385436-60-2P 385436-62-4P
 385436-64-6P 385436-65-7P 385436-75-9P
 385436-76-0P 385436-79-3P 385436-80-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (prepn. of amino acid benzophenone and sulfone derivs. as inhibitors of
 glycine uptake)

RN 385436-18-0 CAPLUS


CN Glycine, N-methyl-N-[3-phenyl-3-[4-(3-thienylsulfonyl)phenoxy]propyl]-,
 hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 385436-35-1 CAPLUS

CN Glycine, N-[3-[4-(benzo[b]thien-2-ylcarbonyl)phenoxy]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 385436-37-3 CAPLUS

CN Glycine, N-[3-[4-(2-benzofuranylcarbonyl)phenoxy]-3-phenylpropyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)


09/757,011



● HCl

RN 385436-59-9 CAPLUS


CN Glycine, N-[3-(4-fluorophenyl)-3-[4-(3-thienylcarbonyl)phenoxy]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 385436-60-2 CAPLUS

CN Glycine, N-[3-[4-(benzo[b]thien-2-ylcarbonyl)phenoxy]-3-(4-fluorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 385436-62-4 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-[4-(2-thiazolylcarbonyl)phenoxy]propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 385436-64-6 CAPLUS
CN Glycine, N-[3-(4-fluorophenyl)-3-[4-[(5-methyl-2-thiazolyl)carbonyl]phenoxy]propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 385436-65-7 CAPLUS
CN Glycine, N-[3-[4-(2-benzothiazolylcarbonyl)phenoxy]-3-(4-fluorophenyl)propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


09/757,011



● HCl

RN 385436-75-9 CAPLUS


CN Glycine, N-[3-(4-chlorophenyl)-3-[4-(3-thienylcarbonyl)phenoxy]propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 385436-76-0 CAPLUS


CN Glycine, N-[3-[4-(benzo[b]thien-2-ylcarbonyl)phenoxy]-3-(4-chlorophenyl)propyl]-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 385436-79-3 CAPLUS


CN Glycine, N-[3-(4-chlorophenyl)-3-[4-(2-thiazolylcarbonyl)phenoxy]propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 385436-80-6 CAPLUS

CN Glycine, N-[3-(4-chlorophenyl)-3-[4-[(5-methyl-2-thiazolyl)carbonyl]phenoxy]propyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2002 ACS

AN 2001:132748 CAPLUS

DN 134:178816

TI Preparation of amino acid derivatives as pharmaceuticals for treatment of neurological and neuropsychiatric disorders

IN Ognyanov, Vassil Iliya; Borden, Laurence A.; Bell, Stanley Charles; Zhang, Jing

PA Allelix Neuroscience Inc., USA

SO U.S., 52 pp., Cont.-in-part of U. S. Ser. No.656,063, abandoned.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6191165	B1	20010220	US 1997-866007	19970530
	US 2001012857	A1	20010809	US 2001-757011	20010109
PRAI	US 1996-41503P	P	19960531		
	US 1996-41504P	P	19960531		
	US 1996-655912	B2	19960531		
	US 1996-656063	B2	19960531		
	US 1997-44387P	P	19970227		
	US 1997-70900P	P	19970227		
	US 1997-808754	B2	19970227		
	US 1997-808755	A2	19970227		
	US 1997-807682	A2	19970228		
	US 1997-866007	A3	19970530		

OS MARPAT 134:178816

AB Amino acid derivs. R2RxRyXR1NR3(R3*)nCR4R4*R5 [X = N, C (R2 not present when X = N); R2 = H, alkyl, alkoxy, cyano, alkanoyl, etc.; Rx, Ry = aryl, heteroaryl, adamantyl, or nonarom. ring linked to X via a single bond, alkylene, etc.; R1 = alkylene, iminoxyethylene, etc.; R3 = H, alkyl, (un)substituted Ph or phenylalkyl, etc.; R3* = alkyl, O; n = 0, 1; R4, R4* = H, alkyl, hydroxyalkyl; R5 = (un)substituted carbamoyl, carboxy, aminosulfonyl, phosphoryl, etc.] were prepd. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders. Thus, N-(4,4-diphenyl-3-butenyl)glycine Et ester was by alkylation of glycine Et ester hydrochloride with 4-bromo-1,1-diphenyl-1-butene. Binding assays to measure interaction of compds. with the glycine site on the NMDA receptor are illustrated.


IT 200005-41-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of amino acid derivs. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders)

RN 200005-41-0 CAPLUS

CN Glycine, N-[3-hydroxy-3-phenyl-3-(2-thienyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




IT 200005-01-2P 200005-43-2P 200005-44-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of amino acid derivs. as pharmaceuticals for treatment of
 neurol. and neuropsychiatric disorders)


RN 200005-01-2 CAPLUS

CN Glycine, N-[3-(1,3-benzodioxol-5-yloxy)-3-(4-chlorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-43-2 CAPLUS

CN Glycine, N-[3-(2-furanyl)-3-hydroxy-3-phenylpropyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 200005-44-3 CAPLUS

CN Glycine, N-methyl-N-[3-phenyl-3-(2-thienyl)propyl]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L38 A~~

AN 1998:682112 CAPLUS

TI Anti-infla

IN Semple, Graeme; Junien, Jean-Louis; Kendrick, David Alan

SO PCT Int. Appl., 19 pp.

DT Patent

FAN.CNT 1


PATE

PI	WO 9843629	A1	19981008	WO 1998-GB976	19980402
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	GB 2323783	A1	19981007	GB 1997-6652	19970402
	AU 9868474	A1	19981022	AU 1998-68474	19980402
PRAI	GB 1997-6652		19970402		
	WO 1998-GB976		19980402		

AB Medicament contg. inhibitors of farnesyl protein transferase are claimed for the treatment of an inflammatory pathol. condition or the assocd. **pain.** Thus, 1-(2-amino-3-mercaptopropyl)-2-butyl-4-(1-naphthoyl)piperazine, at a concn. of 1 .mu.M, inhibited the proliferation of cultured human T-lymphocytes by 72%.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-inflammatory medicament contg. farnesyl protein transferase inhibitors)

CN Pentanamide, 2-[[(2S,4R)-4-amino-5-mercapto-2-[(1S)-1-methylpropyl]pentyl]amino]-3-methyl-N-[(3S)-tetrahydro-2-oxo-3-furanyl]-, (2S,3S)- (9CI) (CA INDEX NAME)



applicants

L36 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2002 ACS

AN 1997:803807 CAPLUS

DN 128:48490

TI Preparation of amino acid derivatives as pharmaceuticals for treatment of neurological and neuropsychiatric disorders

IN Ognyanov, Vassil Iliya; Borden, Laurence; Bell, Stanley Charles; Zhang, Jing

PA Trophix Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9745115	A1	19971204	WO 1997-US9450	19970529
	W:		AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
	CA 2254833	AA	19971204	CA 1997-2254833	19970529
	AU 9731530	A1	19980105	AU 1997-31530	19970529
	AU 730789	B2	20010315		
	EP 1014966	A1	20000705	EP 1997-926871	19970529
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		
	BR 9709501	A	20001107	BR 1997-9501	19970529
	CN 1327383	A	20011219	CN 1997-196821	19970529
	JP 2002515037	T2	20020521	JP 1997-543034	19970529
	NO 9805711	A	19981207	NO 1998-5711	19981207
PRAI	US 1996-655912	A	19960531		
	US 1996-656063	A	19960531		
	US 1997-808754	A	19970227		
	US 1997-808755	A	19970227		
	US 1997-807682	A	19970227		
	WO 1997-US9450	W	19970529		
OS	MARPAT 128:48490				
AB	Amino acid derivs. R2RxRyXR1NR3(R3*)nCR4R4*R5 [X = N, C (R2 not present when X = N); R2 = H, alkyl, alkoxy, cyano, alkanoyl, etc.; Rx, Ry = aryl, heteroaryl, adamantyl, or nonarom. ring linked to X via a single bond, alkylene, etc.; R1 = alkylene, iminoxyethylene, etc.; R3 = H, alkyl, (un)substituted Ph or phenylalkyl, etc.; R3* = alkyl, O; n = 0, 1; R4, R4* = H, alkyl, hydroxyalkyl; R5 = (un)substituted carbamoyl, carboxy, aminosulfonyl, phosphoryl, etc.] were prep'd. as pharmaceuticals for treatment of neurol. and neuropsychiatric disorders. Thus, N-(4,4-diphenyl-3-butenyl)glycine Et ester was by alkylation of glycine Et ester hydrochloride with 4-bromo-1,1-diphenyl-1-butene. Binding assays to measure interaction of compds. with the glycine site on the NMDA receptor are illustrated.				
IT	200005-41-0P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)				

(prepn. of amino acid derivs. as pharmaceuticals for treatment of
neuro. and neuropsychiatric disorders)

RN 200005-41-0 CAPLUS

CN Glycine, N-[3-hydroxy-3-phenyl-3-(2-thienyl)propyl]-N-methyl-, ethyl ester
(9CI) (CA INDEX NAME)




IT 200005-01-2P 200005-43-2P 200005-44-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of amino acid derivs. as pharmaceuticals for treatment of
neuro. and neuropsychiatric disorders)


RN 200005-01-2 CAPLUS

CN Glycine, N-[3-(1,3-benzodioxol-5-yloxy)-3-(4-chlorophenyl)propyl]-N-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 200005-43-2 CAPLUS

CN Glycine, N-[3-(2-furanyl)-3-hydroxy-3-phenylpropyl]-N-methyl-, ethyl ester
(9CI) (CA INDEX NAME)



RN 200005-44-3 CAPLUS

CN Glycine, N-methyl-N-[3-phenyl-3-(2-thienyl)propyl]-, ethyl ester (9CI)
(CA INDEX NAME)



09/757,011

136 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2002 ACS

AN 1990:632059 CAPLUS

DN 113:232059

TI Preparation of acylpyroglutamates and isoxazolyalalanines and analogs as biological ~~memory~~ enhancers

IN Harada, Setsuo; Nagaoka, Akinobu; Itoh, Katsumi; Terao, Shinji

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 30 pp.


CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 367393	A2	19900509	EP 1989-309430	19890918
	EP 367393	A3	19910327		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 03173864	A2	19910729	JP 1989-235123	19890911
	US 5021439	A	19910604	US 1989-408389	19890918
PRAI	JP 1988-276919		19881031		
	JP 1989-95595		19890414		
	JP 1989-222241		19890829		
	JP 1989-235123		19890911		
OS	MARPAT 113:232059				
GI					



AB The title compds. [I and II; R1 = H, C-connected org. residue; R2 = H, protecting group; R3 = H, ester or amide residue; R4, R5 = H, acyl, (aryl-substituted) hydrocarbonyl; NR4R5 = ring, (substituted) benzylidene; X = O, NOH; n = 0-3], were prepd. Thus, Me (R)-N-tert-butoxycarbonylpyroglutamate in THF at -78.degree. was treated with LiN(CHMe2)2 and then HCO2CHMe2 to give 29% II (R1 = H, R3 = OMe, R4 = Me3CO2C, X = O, n = 1). The latter was oximated and then treated successively with NaOH in MeOH, aq. NaOH, and HCl/dioxane to give title isoxazalone III. III at 10 mg/kg i.p. in mice increased latency in a light-dark shock test from 100% (cycloheximide-impaired controls) to 278%. Tablet and injection formulations of III.Na are given.

IT 130619-80-6P 130621-45-3P


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as glutamate agonist-~~memory~~ enhancer)

RN 130619-80-6 CAPLUS

CN 4-Isoxazolepropanoic acid, 2,5-dihydro-.alpha.-[(1-methyl-3-


09/757,011

phenylpropyl)amino]-5-oxo- (9CI) (CA INDEX NAME)




RN 130621-45-3 CAPLUS

CN 4-Isioxazolepropanoic acid, 2,5-dihydro-.alpha.-[(1-methyl-3-phenylpropyl)amino]-5-oxo-, monosodium salt (9CI) (CA INDEX NAME)



● Na

C:\STNEXP4\QUERIES\09757011b.str



chain nodes :

4 5 6 7 8 9 10 11 16 17 21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 36 37 38 39 40

ring/chain nodes :

1 2 3

chain bonds :

1-21 4-5 6-11 7-10 8-9 16-17 21-22 23-24 25-26 26-27 28-29
29-30 30-31 32-33 33-34 35-36 36-37 38-39 39-40

ring/chain bonds :

1-2 1-3

exact/norm bonds :

1-2 1-3 1-21 21-22 28-29 29-30 32-33 35-36 38-39

exact bonds :


4-5 6-11 7-10 8-9 16-17 23-24 25-26 26-27 30-31 33-34 36-37
39-40

G1:C,O,S,N,[*1],[*3],[*4],[*5],[*6]

G2:[*7-*8],[*9-*10],[*11-*12],[*13-*14],[*15-*16],[*17-*18]

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS
9:CLASS 10:CLASS 11:CLASS 16:CLASS 17:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS
37:CLASS 38:CLASS 39:CLASS 40:CLASS



chain nodes :

4 5 6 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 24 25
 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50
 51 66 70 71 78 79 80 81 83 84 85 87 98 100

ring nodes :

23 73 74 75 76 77 86 88 89 90 91 92

ring/chain nodes :

1 2 3 7

chain bonds :

1-2 2-3 3-4 4-33 4-100 5-6 5-7 7-70 7-71 8-9 8-10 10-98 11-12
 11-13 13-85 14-15 14-16 14-23 17-18 17-19 17-24 19-78 20-21
 20-22 20-25 21-81 22-80 24-79 34-35 36-37 37-38 39-40 40-41
 41-42 43-44 44-45 46-47 47-48 49-50 50-51 83-84 84-87 85-86

ring bonds :

23-73 23-77 73-74 74-75 75-76 76-77 86-88 86-92 88-89 89-90
 90-91 91-92

exact/norm bonds :

1-2 2-3 3-4 4-33 4-100 5-6 5-7 7-70 7-71 8-9 8-10 10-98 11-12
 11-13 14-15 14-16 14-23 17-18 17-19 17-24 19-78 20-21 20-22
 23-73 23-77 24-79 39-40 40-41 43-44 46-47 49-50 73-74 74-75
 75-76 76-77

exact bonds :

13-85 20-25 21-81 22-80 34-35 36-37 37-38 41-42 44-45 47-48
 50-51 83-84 84-87 85-86

normalized bonds :

86-88 86-92 88-89 89-90 90-91 91-92

G4:[*8-*9], [*10-*11], [*12-*13], [*14-*15], [*16-*17], [*18-*19]

G5:H, Et

G6:H, CH3, Et, n-Pr, i-Pr, n-Bu, t-Bu, Ph, [*20]

G7:H, CH3, Et, n-Pr, i-Pr

Match level :

1:CLASS	2:CLASS	3:CLASS	4:CLASS	5:CLASS	6:CLASS	7:CLASS	8:CLASS
9:CLASS	10:CLASS	11:CLASS	12:CLASS	13:CLASS	14:CLASS	15:CLASS	
16:CLASS	17:CLASS	18:CLASS	19:CLASS	20:CLASS	21:CLASS	22:CLASS	
23:CLASS	24:CLASS	25:CLASS	33:CLASS	34:CLASS	35:CLASS	36:CLASS	
37:CLASS	38:CLASS	39:CLASS	40:CLASS	41:CLASS	42:CLASS	43:CLASS	
44:CLASS	45:CLASS	46:CLASS	47:CLASS	48:CLASS	49:CLASS	50:CLASS	
51:CLASS	66:Atom	70:CLASS	71:CLASS	73:Atom	74:Atom	75:Atom	76:Atom
77:Atom	78:CLASS	79:CLASS	80:CLASS	81:CLASS	83:CLASS	84:CLASS	
85:CLASS	86:Atom	87:CLASS	88:Atom	89:Atom	90:Atom	91:Atom	92:Atom
98:CLASS	100:CLASS						

Element Count :

Node 66: Limited

N, N4

C, C1